2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
Upcoming 2021 CVS Formulary Changes
Understanding the importance of delivering “an effective formulary strategy” to achieve cost containment in these challenging times, CVS has revealed their 2021 formulary changes.
Read Post
Upcoming 2021 OptumRx Formulary Changes
Looking toward 2021, OptumRx has announced its formulary changes effective January 1, 2021. These changes will include a combination of downtiers, uptiers, and exclusions…
Read Post
President Trump’s Executive Order on Lowering Drug Prices
Most-Favored-Nation Price for Medicare Back on July 24 of this year, President Trump announced four executive orders taking a variety of approaches to address…
Read Post
The RFP: Your ticket to prior authorizations that work
Managing drug cost and trend is like wrangling an octopus—it’s a constant fight to control the various factors that contribute to rising drug prices.
Read Post
Artemetrx Announces Partnership with Blue Cross and Blue Shield of Kansas City to Deliver Drug Cost Savings Insights to Plan Sponsors via the Artemetrx Platform
Artemetrx data and analytics platform integrates medical and pharmacy data to deliver immediate, actionable drug cost savings opportunities – needed now more than ever…
Read Post
Upcoming 2021 Express Scripts Formulary Changes
It’s that time of year again, and Express Scripts has released its list of formulary changes that will be effective January 1, 2021, for…
Read Post
Pharmaceutical Strategies Group appears on Inc 5000 for fourth year in a row
(PLANO, TX – August 20, 2020) – Pharmaceutical Strategies Group (PSG), a leading pharmacy intelligence and technology company providing innovative drug management solutions to self-insured…
Read Post
FDA Delayed Approval of Gene Therapy Drug
Why is Roctavian in the news?It was expected to be the most expensive drug ever approved by the Food and Drug Administration (FDA), at…
Read Post
Why a Public Employee Health Plan Sponsor Ultimately Rejected Their PBM’s Prior Authorization Criteria for Multiple Sclerosis
To reduce costs, pharmacy benefit managers (PBMs) and plan sponsors often implement utilization management (UM) strategies, such as prior authorizations (PAs) and step therapies,…
Read Post
Are prior authorizations and step therapy always the right approach for plan sponsors?
Utilization management (UM) programs are intended to save plan sponsors money and ensure that patients are using the most cost-effective, clinically appropriate medications. However,…
Read Post
What You Need to Know About Spravato
There is no shortage of news articles outlining the increase in depression and anxiety across the US with the COVID pandemic and social distancing…
Read Post